Inclusion Body Myositis with Neck Muscle Weakness and Positive Effect of Immunoglobulins – a Case Report

Česká verzia

Authors: E. Ehler ¹; A. Meleková ¹; J. Latta ¹; P. Mandysová ¹; P. Vojtíšek ²; J. Zámečník ³
Authors place of work: Neurologická klinika FZS Univerzity Pardubice a Pardubické krajské nemocnice, a. s. ¹; Interní klinika FZS Univerzity Pardubice a Pardubické krajské nemocnice, a. s. ²; Ústav patologie a molekulární medicíny 2. LF UK a FN v Motole, Praha ³
Published in the journal: Cesk Slov Neurol N 2013; 76/109(3): 362-366
Category: Kazuistika

Summary

Inclusion body myositis is the most frequent inflammatory myopathy in patients aged 50 years and above. There is a chronic-progredient course of the disease without attacks and remissions. Typical clinical findings consist of proximal and distal weakness of extremity muscles and of axial muscles. Deep finger flexors of the upper extremities, quadriceps and muscles of the anterior compartment of the shin are severely affected. Dysphagia is a typical sign. Weakness of the neck muscles with a tilting head represents a rare and atypical form. We report a case of a 59-year old woman with progredient muscle weakness and atrophy with head tilting forward and dysphagia. Prednisone therapy was ineffective. After repeated intravenous administration of large immunoglobulin doses (60 g every four weeks), the posture of head a neck improved and dysphagia disappeared. One year into the treatment, immunoglobulin therapy is still highly effective.

Key words:
inclusion body myositis – dysphagia – weakness – immunoglobulins

Zdroje

1. Amato AA, Russel JA. Neuromuscular disorders. New York: McGraw Hill Medical 2008.

2. Ambler Z. Zánětlivé myopatie. Neurol Prax 2004; 5: 150–154.

3. Solorzano GE, Phillips LH 2nd. Inclusion body myositis: diagnosis, pathogenesis, and treatment options. Rheum Dis Clin N Am 2011; 37(2): 173–183.

4. Bednařík J et al. Nemoci kosterního svalstva. Praha: Triton 2001.

5. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostics and therapeutic approaches. Lancet Neurol 2007; 6(7): 620–631.

6. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001; 29(1): 83–87.

7. Pourmand R. Immune-mediated neuromuscular diseases. Basel: Karger 2009.

8. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134(11): 3167–3175.

9. Oh SJ. Clinical electromyography. Case studies. Baltimore: Williams & Wilkins 1998.

10. De Bleecker JL, Engel AG, Ertl BB. Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins. J Neuropathol Exp Neurol 1996; 55(5): 563–577.

11. Bednařík J, Voháňka S, Ehler E, Ambler Z, Piťha J, Vencovský J et al. Standard pro léčbu s autoimunitními nervosvalovými onemocněními intravenózním lidským imunoglobulinem a plazmaferézou. Cesk Slov Neurol N 2010; 73/106(5): 570–589.

12. Patwa HS, Chaudry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78(13): 1009–1015.

13. Mahjneh I, Marconi G, Paetau A, Saarinen A, Salmi T, Somer H. Axial myopathy – an unrecognised entity. J Neurol 2002; 249(6): 730–734.